NervGen Pharma (NGEN) Financial Statements

87 Followers

NervGen Pharma Financial Overview

NervGen Pharma's market cap is currently $293.78M. The company's EPS TTM is $-0.26475444; its P/E ratio is -3.19; NervGen Pharma is scheduled to report earnings on March 31, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Mar 25	Mar 24	Dec 22	Dec 21
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ -58.23K	$ -109.40K	$ -84.92K	$ -33.70K
Operating Income	$ -25.08M	$ -17.33M	$ -13.41M	$ -16.99M	$ -10.13M
EBITDA	$ -5.65M	$ -16.62M	$ -16.78M	$ -14.82M	$ -10.03M
Net Income	$ -44.12M	$ -16.68M	$ -16.89M	$ -15.29M	$ -10.06M
Balance Sheet
Cash & Short-Term Investments	$ 22.07M	$ 12.07M	$ 8.80M	$ 16.56M	$ 13.38M
Total Assets	$ 23.21M	$ 13.54M	$ 9.99M	$ 17.61M	$ 14.15M
Total Debt	$ 8.37K	$ 73.38K	$ 148.78K	$ 209.10K	$ 0.00
Net Debt	$ -22.06M	$ -11.93M	$ -8.65M	$ -16.35M	$ -13.38M
Total Liabilities	$ 19.73M	$ 11.75M	$ 11.50M	$ 7.68M	$ 852.33K
Stockholders' Equity	$ 3.48M	$ 1.79M	$ -1.52M	$ 9.93M	$ 13.30M
Cash Flow
Free Cash Flow	$ -19.50M	$ -11.70M	$ -8.53M	$ -13.13M	$ -6.54M
Operating Cash Flow	$ -19.50M	$ -11.70M	$ -8.52M	$ -13.12M	$ -6.54M
Investing Cash Flow	$ 100.93K	$ 40.91K	$ -104.77K	$ -15.57K	$ -35.64K
Financing Cash Flow	$ 23.76M	$ 15.77M	$ 578.16K	$ 16.70M	$ 15.51M

Currency in USD

NervGen Pharma Earnings and Revenue History

Income Statement >

NervGen Pharma Debt to Assets

Balance Sheet >

NervGen Pharma Cash Flow

Cash Flow >

NervGen Pharma Forecast EPS vs Actual EPS

Earnings >